|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0005938,
umls-concept:C0006142,
umls-concept:C0016658,
umls-concept:C0021149,
umls-concept:C0043210,
umls-concept:C0232970,
umls-concept:C0521324,
umls-concept:C0679823,
umls-concept:C0681867,
umls-concept:C0851344,
umls-concept:C1280500,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2007-2-1
|
|
pubmed:abstractText |
Tamoxifen preserves bone in postmenopausal women, but non-steroidal aromatase inhibitors accelerate bone loss and increase fracture risk. We aimed to study the effect on bone health in a subgroup of women included in the Intergroup Exemestane Study (IES), a large randomised trial that compared the switch to the steroidal aromatase inhibitor exemestane with continuation of tamoxifen in the adjuvant treatment of postmenopausal breast cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1470-2045
|
|
pubmed:author |
pubmed-author:BanksLinda MLM,
pubmed-author:BlissJudith MJM,
pubmed-author:CawthornSimon JSJ,
pubmed-author:ColemanRobert ERE,
pubmed-author:CoombesR CharlesRC,
pubmed-author:FoxJohnJ,
pubmed-author:GirgisSamia ISI,
pubmed-author:HallEmmaE,
pubmed-author:Intergroup Exemestane Study group,
pubmed-author:KilburnLucy SLS,
pubmed-author:PatelAshrafA,
pubmed-author:SnowdonClaire FCF,
pubmed-author:VrdoljakEduardE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
119-27
|
|
pubmed:meshHeading |
pubmed-meshheading:17267326-Androstadienes,
pubmed-meshheading:17267326-Antineoplastic Agents,
pubmed-meshheading:17267326-Biological Markers,
pubmed-meshheading:17267326-Bone Density,
pubmed-meshheading:17267326-Bone Remodeling,
pubmed-meshheading:17267326-Breast Neoplasms,
pubmed-meshheading:17267326-Female,
pubmed-meshheading:17267326-Follow-Up Studies,
pubmed-meshheading:17267326-Fractures, Bone,
pubmed-meshheading:17267326-Hip,
pubmed-meshheading:17267326-Humans,
pubmed-meshheading:17267326-Incidence,
pubmed-meshheading:17267326-Lumbar Vertebrae,
pubmed-meshheading:17267326-Postmenopause,
pubmed-meshheading:17267326-Risk Factors,
pubmed-meshheading:17267326-Spine,
pubmed-meshheading:17267326-Tamoxifen,
pubmed-meshheading:17267326-Time Factors,
pubmed-meshheading:17267326-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
|
|
pubmed:affiliation |
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK. R.E.Coleman@sheffield.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
